Dec 3, 2024
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with Luís Valente, CEO of iLOF, a deep-tech health startup, who shared insights on revolutionising personalised medicine. iLOF leverages Optomics—an innovative combination of optical data and AI—to overcome challenges in clinical trials, such as invasive procedures and recruitment inefficiencies. Luis highlights the startup’s impactful partnership in an ambitious Alzheimer’s trial and reflects on the demanding, often misunderstood role of a startup CEO. He offers advice for transitioning from corporates to startups, emphasising stage-appropriate involvement and culture alignment. Success hinges on hiring motivated people, fostering purpose, and prioritising high-performing teams over micromanaging the unmotivated. 🚀
Luís
Valente, CEO & Co-Founder @ iLoF Business manager,
strategist, and entrepreneur with a drive for using innovative and
creative strategies to solve complex problems. Forbes 30 under 30
for Science and Healthcare, with a background in Computer Science,
I have spent several years focusing on innovation and improving
strategies in companies from Tech to Healthcare.
My passion for entrepreneurship led me to create my first business
at 18, founding and operating several ventures specializing in
optimized demand prediction, lean operations, and design for
growth. A deep belief in the power of Technology as the core driver
for democratizing Personalized Medicine had me co-founding iLoF: a
fast-growing deep tech company using AI to build a cloud-based
library of disease biomarkers and biological profiles.
Currently on a mission to accelerate adequate treatments for
millions of patients living with complex, heterogeneous diseases
around the globe.
Other relevant references | Outras referências relevantes:
Contacts | Contactos:
Episode edited by João Cunha Studios